Image credit: Erica Bass, Rogel Cancer Center, Michigan Medicine The treatment head of the Edison Platform, designed for delivering histotripsy treatment. Today, FDA officials awarded clearance to HistoSonics, a company co-founded in 2009 by U-M engineers and doctors for the use of histotripsy to destroy targeted liver tissue.Ī human trial underway since 2021 at the U-M Rogel Cancer Center and other locations has treated patients with primary and metastatic liver tumors via histotripsy, demonstrating the technology’s ability to meet the testing’s primary effectiveness and safety targets. Pioneered at the University of Michigan, histotripsy offers a promising alternative to cancer treatments such as surgery, radiation and chemotherapy, which often have significant side effects.
Food and Drug Administration has approved the use of sound waves to break down tumors-a technique called histotripsy-in humans for liver treatment.
